Watertown, United States
Disc Medicine is a biopharmaceutical company founded in 2017 and based in the United States, with a focus on revolutionizing the treatment landscape for patients with hematologic disorders. Their commitment to making a difference in patients' lives is encapsulated in their slogan: "Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders."
The company is at the forefront of developing an innovative and pioneering portfolio of therapeutic candidates that target the fundamental pathways of red blood cell biology. Their last $178.00M Post-IPO Equity investment on 14 June 2024 drew support from a consortium of prominent investors including Atlas Venture, OrbiMed, Wellington Management, Access Biotechnology, Adage Capital Management, Janus Handerson, Logos Capital, TCG Crossover, Paradigm BioCapital Advisors, and Frazier Life Sciences.
With a focus on the intersection of biotechnology, health care, and the pharmaceutical industry, Disc Medicine is poised to make a significant impact in the field and has garnered substantial support from the investment community, cementing its position as a key player in the biopharmaceutical landscape.
